Charles W Lynde

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1994672/publications.pdf

Version: 2024-02-01

304743 345221 53 1,436 22 36 citations h-index g-index papers 55 55 55 1446 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. Journal of Allergy and Clinical Immunology, 2022, 149, 977-987.e14.	2.9	66
2	The Impact of Acne Treatment on Skin Bacterial Microbiota: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2022, 26, 93-97.	1.2	9
3	Risk of Vulvar Squamous Cell Carcinoma in Lichen Sclerosus and Lichen Planus: A Systematic Review. Journal of Obstetrics and Gynaecology Canada, 2022, 44, 182-192.	0.7	11
4	Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a realâ€world setting. British Journal of Dermatology, 2022, 186, 726-728.	1.5	3
5	Treatments for Primary Delusional Infestation: Systematic Review. JMIR Dermatology, 2022, 5, e34323.	0.7	4
6	Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers. Journal of Cutaneous Medicine and Surgery, 2022, 26, 267-273.	1.2	4
7	Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies. Journal of Cutaneous Medicine and Surgery, 2022, 26, 3S-23S.	1.2	6
8	Impacts of COVID-19 on Dermatologic Practice, Disease Presentation, and Immunomodulator Prescriptions. Journal of Cutaneous Medicine and Surgery, 2021, 25, 106-108.	1.2	3
9	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52Aweeks (PSO-LONG trial). Journal of the American Academy of Dermatology, 2021, 84, 1269-1277.	1.2	38
10	A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Frontiers in Medicine, 2021, 8, 702776.	2.6	9
11	Gaps and recommendations for clinical management of truncal acne from the Personalising Acne: Consensus of Experts panel. JAAD International, 2021, 5, 33-40.	2.2	7
12	Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panel. JAAD International, 2021, 5, 41-48.	2.2	6
13	The Personalised Acne Care Pathwayâ€"Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts. JAAD International, 2021, 5, 101-111.	2.2	8
14	Prurigo Nodularis: Review and Emerging Treatments. Skin Therapy Letter, 2021, 26, 5-8.	0.3	3
15	Moisturizers and Cleansers in the Management of Skin Conditions Caused by Personal Protective Equipment and Frequent Handwashing. Skin Therapy Letter, 2021, 26, 9-13.	0.3	1
16	A randomized phase $3b/4$ study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 -mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. Journal of the American Academy of Dermatology, 2020, 82, 336-343.	1.2	42
17	Diagnosis and Management of Atopic Dermatitis for Primary Care Providers. Journal of the American Board of Family Medicine, 2020, 33, 626-635.	1.5	8
18	Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis. Journal of Cutaneous Medicine and Surgery, 2020, 24, 625-632.	1.2	5

#	Article	IF	CITATIONS
19	A Call for Critical Analysis of Teledermatology. Journal of Cutaneous Medicine and Surgery, 2020, 24, 648-648.	1.2	0
20	Common Atopic Dermatitis Rating Scales: A Practical Approach and Brief Review. Journal of Cutaneous Medicine and Surgery, 2020, 24, 399-404.	1.2	6
21	Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2020, 24, 174-186.	1.2	29
22	Adult-Onset Atopic Dermatitis: Presentations and Progress. Journal of Cutaneous Medicine and Surgery, 2020, 24, 267-272.	1.2	20
23	A Brief History of Psoriasis Management in Canada. Journal of Cutaneous Medicine and Surgery, 2020, 24, 273-277.	1.2	1
24	Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders. Journal of Cutaneous Medicine and Surgery, 2019, 23, 27S-34S.	1.2	27
25	Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. Journal of Cutaneous Medicine and Surgery, 2019, 23, 282-288.	1.2	3
26	Clinical Insights About Topical Treatment of Mild-to-Moderate Pediatric and Adult Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2019, 23, 3S-13S.	1.2	6
27	Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents. Journal of Cutaneous Medicine and Surgery, 2019, 23, 204-221.	1.2	28
28	Shifting the focus – the primary role of <scp>IL</scp> â€23 in psoriasis and other inflammatory disorders. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1111-1119.	2.4	80
29	Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. American Journal of Clinical Dermatology, 2018, 19, 437-447.	6.7	26
30	A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. Journal of Cutaneous Medicine and Surgery, 2018, 22, 78-83.	1.2	17
31	Comparison of the Treatment Guidelines for Actinic Keratosis: A Critical Appraisal and Review. Journal of Cutaneous Medicine and Surgery, 2017, 21, 408-417.	1.2	22
32	Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults. International Journal of STD and AIDS, 2017, 28, 1433-1443.	1.1	13
33	Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1188-1195.	2.4	16
34	Acitretin Use in Dermatology. Journal of Cutaneous Medicine and Surgery, 2017, 21, 2S-12S.	1.2	27
35	Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. Journal of Cutaneous Medicine and Surgery, 2017, 21, 513-524.	1.2	39
36	Review of Systemic Treatment Options for Adult Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2017, 21, 31-39.	1.2	42

#	Article	IF	Citations
37	Advances in Understanding and Managing Chronic Urticaria. F1000Research, 2016, 5, 177.	1.6	16
38	Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1115-1119.	2.4	25
39	Chronic Spontaneous Urticaria (CSU). Journal of Cutaneous Medicine and Surgery, 2016, 20, 308-312.	1.2	5
40	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis. JAMA Dermatology, 2016, 152, 661.	4.1	46
41	Management of acne: Canadian clinical practice guideline. Cmaj, 2016, 188, 118-126.	2.0	67
42	The Relationship of Obesity With the Severity of Psoriasis. Journal of Cutaneous Medicine and Surgery, 2015, 19, 450-456.	1.2	68
43	Think beyond the Skin. Journal of Cutaneous Medicine and Surgery, 2015, 19, 22-27.	1.2	31
44	Canadian Guidelines for the Management of Plaque Psoriasis: Overview. Journal of Cutaneous Medicine and Surgery, 2011, 15, 210-219.	1.2	76
45	Use of Biologic Therapeutics in Difficult-to-Treat Psoriasis. Journal of Cutaneous Medicine and Surgery, 2009, 13, 6-17.	1.2	0
46	Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 1188-1193.	2.4	37
47	Alefacept: clinical use in treating psoriasis. Expert Review of Dermatology, 2006, 1, 781-790.	0.3	0
48	Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis. Journal of Cutaneous Medicine and Surgery, 2005, 9, 1-3.	1.2	1
49	Pyogenic Granuloma: Pyogenic Again? Association between Pyogenic Granuloma and Bartonella. Journal of Cutaneous Medicine and Surgery, 2001, 5, 467-470.	1.2	14
50	Therapeutic Options for the Treatment of Tinea Capitis Caused by Trichophyton Species: Griseofulvin Versus the New Oral Antifungal Agents, Terbinafine, Itraconazole, and Fluconazole. Pediatric Dermatology, 2001, 18, 433-438.	0.9	133
51	Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study. British Journal of Dermatology, 2000, 142, 965-968.	1.5	58
52	Carbon Dioxide Laser-Treatment of Resistant Verrucae Vulgaris: Retrospective Analysis. Journal of Cutaneous Medicine and Surgery, 1998, 2, 142-145.	1.2	35
53	Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. International Journal of Dermatology, 1997, 36, 783-787.	1.0	184